ReviewCurrent cancer drug targets2025
A Comprehensive Review on Anticancer Potential of
Review in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Pulicaria, belonging to the Asteraceae family, includes 100 species distributed from Europe to North Africa and Asia, especially around the Mediterranean. A number of extracts and compounds of this genus have been found to have anticancer effects on various cancer cell lines. Google, PubMed, Web of Science and Scopus databases were searched for articles related to Pulicaria or its isolated compounds. The search was conducted using various keywords, including "Pulicaria and anticancer activity". After the review, the relevant articles were summarized and included in the review article. Fortunately, the results of this review showed that relatively comprehensive studies have been conducted in this field, and the presence of various compounds in these plants can be used in cancer research. The results of our review showed that Pulicaria vulgaris has the strongest effect and Pulicaria dysenterica has the weakest effect on cancer cells. Future studies should focus on finding purer compounds and investigating the anticancer effects of these compounds. These herbal compounds can also be used alongside standard drugs to treat cancer, especially to reduce the effect of drug resistance.
Indexed as
Identifiers
39945254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.